Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity. The company is backed by top-tier investors, including Westlake Village BioPartners, 5AM Ventures, Foresite Capital, and Corner Ventures.
Company Details
- Employees
- 44
- Address
- Thousand Oaks, Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.latigobio.com
- Keywords
- in clinical pharmacology.
- HQ
- Thousand Oaks, CA
Latigo Biotherapeutics, Inc. Questions
Latigo Biotherapeutics, Inc.'s website is http://www.latigobio.com
Latigo Biotherapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/latigobio
Latigo Biotherapeutics, Inc. has
44 employees.
View email and phone details for 44
employees at Latigo Biotherapeutics, Inc..
Latigo Biotherapeutics, Inc.'s industry is
Biotechnology Research
Latigo Biotherapeutics, Inc.'s top competitors are
Juvena Therapeutics,
Laguna Source,
Curevo Vaccine,
Henlius Usa Inc.,
Light Horse Therapeutics,
Blossomhill Therapeutics, Inc.,
Ixcells Biotechnologies,
Capsida Biotherapeutics,
Aditum Bio,
Newlimit.
Latigo Biotherapeutics, Inc.'s categories are Biotechnology Research
